Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Mesoblast Limited (MESO : NSDQ)

• Company Description    Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. Number of Employees: 83

• Price / Volume Information    Yesterday's Closing Price: $3.58 Daily Weekly Monthly 20 Day Moving Average: 61,136 shares Shares Outstanding: 130.09 (millions) Market Capitalization: $465.73 (millions) Beta: 3.05 52 Week High: $8.85 52 Week Low: $3.23 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.50% 0.81% 12 Week -8.91% 0.15% Year To Date -25.42% -8.87%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL LEVEL 38 55 COLLINS STREET - MELBOURNE,C3 3000 AUS ph: 61-3-9639-6036 fax: 61-3-9639-6030 schond.greenway@mesoblast.com http://www.mesoblast.com

• General Corporate Information    Officers Silviu Itescu - Chief Executive Officer Joseph R Swedish - Chairman Josh Muntner - Chief Financial Officer Donal O'Dwyer - Director Michael Spooner - Director Peer Information Mesoblast Limited (CORR.) Mesoblast Limited (RSPI) Mesoblast Limited (CGXP) Mesoblast Limited (BGEN) Mesoblast Limited (GTBP) Mesoblast Limited (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 590717104 SIC: 2836 Fiscal Year Fiscal Year End: June Last Reported Quarter: 12/01/21 Next Expected EPS Date: 06/01/22 Share - Related Items Shares Outstanding: 130.09 Most Recent Split Date: (:1) Beta: 3.05 Market Capitalization: $465.73 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.49 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/01/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.87 Price/Cash Flow: - Price / Sales: 47.10 EPS Growth vs. Year Ago Period: 9.09% vs. Previous Quarter: -17.65% Sales Growth vs. Year Ago Period: 6.34% vs. Previous Quarter: -33.70% ROE 03/31/22 - - 12/31/21 - -17.07 09/30/21 - -17.15 ROA 03/31/22 - - 12/31/21 - -13.23 09/30/21 - -13.28 Current Ratio 03/31/22 - - 12/31/21 - 1.88 09/30/21 - 1.36 Quick Ratio 03/31/22 - - 12/31/21 - 1.88 09/30/21 - 1.36 Operating Margin 03/31/22 - - 12/31/21 - -982.76 09/30/21 - -994.48 Net Margin 03/31/22 - - 12/31/21 - -982.76 09/30/21 - -994.48 Pre-Tax Margin 03/31/22 - - 12/31/21 - -985.84 09/30/21 - -996.03 Book Value 03/31/22 - - 12/31/21 - 4.12 09/30/21 - 4.31 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.16 09/30/21 - 0.08 Debt-to-Capital 03/31/22 - - 12/31/21 - 13.91 09/30/21 - 7.08

Powered by Zacks Investment Research ©